Mersana Therapeutics CEO Anna Protopapas' 2019 pay falls 33% to $1.7M
Mersana Therapeutics reports 2019 executive compensation
By ExecPay News
Published: April 27, 2021
Mersana Therapeutics reported fiscal year 2019 executive compensation information on April 27, 2021.
In 2019, five executives at Mersana Therapeutics received on average a compensation package of $1.1M, a 31% decrease compared to previous year.
Average pay of disclosed executives at Mersana Therapeutics
Anna Protopapas, Chief Executive Officer, received $1.7M in total, which decreased by 33% compared to 2018. 31% of Protopapas' compensation, or $533K, was in salary. Protopapas also received $293K in non-equity incentive plan, $507K in option awards, $400K in stock awards, as well as $7K in other compensation.
Dirk Huebner, Chief Medical Officer, received a compensation package of $1.1M. 45% of the compensation package, or $521K, was in non-equity incentive plan.
Brian DeSchuytner, Senior Vice President, Finance & Product Strategy, earned $896K in 2019.
Timothy B. Lowinger, Chief Science and Technology Officer, received $873K in 2019, which decreases by 17% compared to 2018.
Michael Kaufman, Chief Manufacturing Officer, earned $862K in 2019, a 9% decrease compared to previous year.
Related executives
Michael Kaufman
Mersana Therapeutics
Former Chief Manufacturing Officer
Timothy Lowinger
Mersana Therapeutics
Senior Vice President, Chief Science and Technology Officer
Anna Protopapas
Mersana Therapeutics
Chief Executive Officer
Dirk Huebner
Mersana Therapeutics
Chief Medical Officer
Brian DeSchuytner
Mersana Therapeutics
Chief Financial Officer
You may also like
Source: SEC filing on April 27, 2021.